Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Dec 20;7(51):85650-85674.
doi: 10.18632/oncotarget.13333.

MicroRNAs for osteosarcoma in the mouse: a meta-analysis

Junli Chang  1   2 , Min Yao  1   2 , Yimian Li  1   2 , Dongfeng Zhao  1   2 , Shaopu Hu  1   2 , Xuejun Cui  1   2 , Gang Liu  3 , Qi Shi  1   2 , Yongjun Wang  1   2   4 , Yanping Yang  1   2
Affiliations
Review

MicroRNAs for osteosarcoma in the mouse: a meta-analysis

Junli Chang et al. Oncotarget. .

Abstract

Osteosarcoma (OS) is the most common primary malignant bone carcinoma with high morbidity that happens mainly in children and young adults. As the key components of gene-regulatory networks, microRNAs (miRNAs) control many critical pathophysiological processes, including initiation and progression of cancers. The objective of this study is to summarize and evaluate the potential of miRNAs as targets for prevention and treatment of OS in mouse models, and to explore the methodological quality of current studies. We searched PubMed, Web of Science, Embase, Wan Fang Database, VIP Database, China Knowledge Resource Integrated Database, and Chinese BioMedical since their beginning date to 10 May 2016. Two reviewers separately screened the controlled studies, which estimate the effects of miRNAs on osteosarcoma in mice. A pair-wise analysis was performed. Thirty six studies with enough randomization were selected and included in the meta-analysis. We found that blocking oncogenic or restoring decreased miRNAs in cancer cells could significantly suppress the progression of OS in vivo, as assessed by tumor volume and tumor weight. This meta-analysis suggests that miRNAs are potential therapeutic targets for OS and correction of the altered expression of miRNAs significantly suppresses the progression of OS in mouse models, however, the overall methodological quality of studies included here was low, and more animal studies with the rigourous design must be carried out before a miRNA-based treatment could be translated from animal studies to clinical trials.

Keywords: meta-analysis; miRNA; mouse; osteosarcoma; therapeutic target.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST

No conflict of interest was declared.

Figures

Figure 1
Figure 1. Schematic representation of the literature identification and selection process
Figure 2
Figure 2. Meta-analysis of studies evaluating the inhibitory effects on tumor weight after the aberrantly expressed miRNAs were corrected, when all included studies used tumor weight as the major outcome measure were stratified by the function of miRNAs in the pathogenesis of osteosarcoma
SD, standard deviation; CI, confidence interval.
Figure 3
Figure 3. Meta-analysis of included studies evaluating the inhibitory effects on tumor weight after the aberrantly expressed miRNAs were corrected, when studies, reported miRNAs as tumor suppressors
A. or oncogenes B. and used tumor weight as the major outcome measure, were stratified respectively by the miRNA delivery method. SD, standard deviation; CI, confidence interval.
Figure 3
Figure 3. Meta-analysis of included studies evaluating the inhibitory effects on tumor weight after the aberrantly expressed miRNAs were corrected, when studies, reported miRNAs as tumor suppressors
A. or oncogenes B. and used tumor weight as the major outcome measure, were stratified respectively by the miRNA delivery method. SD, standard deviation; CI, confidence interval.
Figure 4
Figure 4. Meta-analysis of included studies evaluating the inhibitory effects on tumor weight after the aberrantly expressed miRNAs were corrected, when all included studies used tumor weight as the major outcome measure were stratified by the names of miRNAs
SD, standard deviation; CI, confidence interval.
Figure 5
Figure 5. Meta-analysis of included studies evaluating the inhibitory effects on tumor weight after the aberrantly expressed miRNAs were corrected, when studies reported miRNAs as tumor suppressors
A. or oncogenes B. used tumor weight as the major outcome measure were stratified by injection sites of osteosarcoma cells. SD, standard deviation; CI, confidence interval.
Figure 5
Figure 5. Meta-analysis of included studies evaluating the inhibitory effects on tumor weight after the aberrantly expressed miRNAs were corrected, when studies reported miRNAs as tumor suppressors
A. or oncogenes B. used tumor weight as the major outcome measure were stratified by injection sites of osteosarcoma cells. SD, standard deviation; CI, confidence interval.
Figure 6
Figure 6. Meta-analysis of included studies evaluating the inhibitory effects on tumor weight after the aberrantly expressed miRNAs were corrected, when studies reported miRNAs as tumor suppressors
A. or oncogenes B. and used tumor weight as the major outcome measure, were stratified by osteosarcoma cell lines used to produce osteosarcoma xenograft models . SD, standard deviation; CI, confidence interval.
Figure 6
Figure 6. Meta-analysis of included studies evaluating the inhibitory effects on tumor weight after the aberrantly expressed miRNAs were corrected, when studies reported miRNAs as tumor suppressors
A. or oncogenes B. and used tumor weight as the major outcome measure, were stratified by osteosarcoma cell lines used to produce osteosarcoma xenograft models . SD, standard deviation; CI, confidence interval.
Figure 7
Figure 7. Meta-analysis of studies evaluating the inhibitory effects on tumor volume after the aberrantly expressed miRNAs were corrected, when all included studies used tumor volume as the major outcome measure were stratified by the function of miRNAs in the pathogenesis of osteosarcoma
SD, standard deviation; CI, confidence interval.
Figure 8
Figure 8. Meta-analysis of included studies evaluating the inhibitory effects on tumor volume after the aberrantly expressed miRNAs were corrected, when studies reported miRNAs as tumor suppressors
A. or oncogenes B. and used tumor volume as the major outcome measure were stratified by the miRNA delivery method. SD, standard deviation; CI, confidence interval.
Figure 8
Figure 8. Meta-analysis of included studies evaluating the inhibitory effects on tumor volume after the aberrantly expressed miRNAs were corrected, when studies reported miRNAs as tumor suppressors
A. or oncogenes B. and used tumor volume as the major outcome measure were stratified by the miRNA delivery method. SD, standard deviation; CI, confidence interval.
Figure 9
Figure 9. Meta-analysis of included studies evaluating the inhibitory effects on tumor volume after the aberrantly expressed miRNAs were corrected, when all included studies used tumor volume as the major outcome measure were stratified by the names of miRNAs
SD, standard deviation; CI, confidence interval.
Figure 10
Figure 10. Meta-analysis of included studies evaluating the inhibitory effects on tumor volume after the aberrantly expressed miRNAs were corrected, when studies reported miRNAs as tumor suppressors
A. or oncogenes B. and used tumor volume as the major outcome measure were stratified by injection sites of osteosarcoma cells. SD, standard deviation; CI, confidence interval.
Figure 10
Figure 10. Meta-analysis of included studies evaluating the inhibitory effects on tumor volume after the aberrantly expressed miRNAs were corrected, when studies reported miRNAs as tumor suppressors
A. or oncogenes B. and used tumor volume as the major outcome measure were stratified by injection sites of osteosarcoma cells. SD, standard deviation; CI, confidence interval.
Figure 11
Figure 11. Meta-analysis of included studies evaluating the inhibitory effects on tumor volume after the aberrantly expressed miRNAs were corrected, when studies reported miRNAs as tumor suppressors
A. or oncogenes B. and used tumor volume as the major outcome measure were stratified by osteosarcoma cell lines used to produce OS xenograft models. SD, standard deviation; CI, confidence interval.
Figure 11
Figure 11. Meta-analysis of included studies evaluating the inhibitory effects on tumor volume after the aberrantly expressed miRNAs were corrected, when studies reported miRNAs as tumor suppressors
A. or oncogenes B. and used tumor volume as the major outcome measure were stratified by osteosarcoma cell lines used to produce OS xenograft models. SD, standard deviation; CI, confidence interval.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Ta HT, Dass CR, Choong PF, Dunstan DE. Osteosarcoma treatment: state of the art. Cancer metastasis reviews. 2009;28:247–263. - PubMed
    1. Miao J, Wu S, Peng Z, Tania M, Zhang C. MicroRNAs in osteosarcoma: diagnostic and therapeutic aspects. Tumour biology. 2013;34:2093–2098. - PubMed
    1. Suzuki M, Wada H, Yoshino M, Tian L, Shigematsu H, Suzuki H, Alaa M, Tamura H, Fujiwara T, Nagato K, Motohashi S, Moriya Y, Hoshino H, et al. Molecular characterization of chronic obstructive pulmonary disease-related non-small cell lung cancer through aberrant methylation and alterations of EGFR signaling. Annals of surgical oncology. 2010;17:878–888. - PubMed
    1. Ogino S, Nosho K, Irahara N, Shima K, Baba Y, Kirkner GJ, Mino-Kenudson M, Giovannucci EL, Meyerhardt JA, Fuchs CS. Negative lymph node count is associated with survival of colorectal cancer patients, independent of tumoral molecular alterations and lymphocytic reaction. The American journal of gastroenterology. 2010;105:420–433. - PMC - PubMed
    1. Croyle MA. Long-term virus-induced alterations of CYP3A-mediated drug metabolism: a look at the virology, immunology and molecular biology of a multi-faceted problem. Expert opinion on drug metabolism & toxicology. 2009;5:1189–1211. - PubMed

MeSH terms